Bacopa monnieri (Brahmi) is an Ayurvedic herb containing bacosides A and B — triterpenoid saponins that modulate serotonergic, dopaminergic, and cholinergic neurotransmission. Bacopa enhances the rate of protein kinase activity in the hippocampus, improving the speed of memory consolidation. It also promotes dendritic branching and increases antioxidant enzyme activity in brain tissue.
Unlike stimulant nootropics, bacopa does NOT improve alertness or reaction time acutely. Its effects are chronic — emerging after 4-12 weeks of consistent use. This makes it complementary to, not a substitute for, caffeine or L-theanine.
Bacopa may increase T4 to T3 conversion; alters thyroid hormone balance
Bacopa has cholinergic activity — may oppose anticholinergics
Additive cholinergic effects — enhanced but also increased side effect risk
Bacopa may have mild calcium channel blocking activity
In vitro CYP inhibition noted; clinical significance uncertain
Not Prohibited
Kongkeaw C et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract.
Roodenrys S et al. Chronic effects of Brahmi on human memory.
Stough C et al. Examining the nootropic effects of Bacopa monnieri.
Calabrese C et al. Effects of a standardized Bacopa monnieri extract on cognitive performance in elderly.
Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated: April 2026
Not medical advice. Based on published clinical research and systematic reviews.